# InMed Pharmaceuticals Focuses on Cannabinoid Therapeutic Development > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabinoid-therapeutic-development-inmed-strategic-shift/ > **Published:** 2026-03-17T14:50:08-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:05:54-04:00 > **Clinical Summary:** Explore InMed Pharmaceuticals' shift to cannabinoid therapeutic development and its impact on clinical cannabinoid product sourcing and industry trends. --- ✦ New CED Clinical Relevance #85 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. ResearchTherapeuticCBD Clinical Summary InMed Pharmaceuticals’ strategic pivot toward therapeutic development and away from commodity cannabinoid production through BayMedica represents a significant industry consolidation that may affect the supply landscape for clinicians sourcing standardized cannabinoid products. This shift reflects growing recognition within the industry that clinical utility and regulatory approval pathways favor proprietary formulations and drug candidates over bulk cannabinoid commodities, which face intense price competition and minimal differentiation. For clinicians, this transition could mean fewer suppliers of raw cannabinoid materials but potentially increased access to rigorously tested, quality-controlled pharmaceutical products designed for specific indications. The move aligns with broader pharmaceutical industry expectations that successful cannabis-derived medicines will require the same development rigor, clinical evidence, and regulatory approval as conventional drugs rather than relying on unregulated botanical products. Clinicians should monitor the development timelines and clinical trial data from InMed’s therapeutic programs to understand which cannabinoid-based treatments may become available through traditional pharmaceutical channels in coming years. The practical takeaway is that clinicians should expect the cannabis market to increasingly stratify between regulated pharmaceutical products with clinical evidence and unregulated botanical products, necessitating careful evaluation of product sourcing and evidence quality when recommending [cannabis-based treatments](https://cedclinic.com/cannabis-medical-clinic-experience-beyond-smoking-vaping/) to patients. Dr. Caplan’s Take “When a company like InMed pivots away from commodity cannabinoid production toward therapeutic development, it signals what we’ve known clinically for years: the future isn’t in isolated compounds or uncontrolled products, but in rigorous drug development that can satisfy both FDA scrutiny and patient safety standards.” Clinical Perspective InMed Pharmaceuticals’ strategic pivot away from cannabinoid commodity production toward therapeutic development highlights an important distinction between the cannabis industry’s current landscape and genuine clinical drug development. While this shift suggests growing recognition that [cannabinoid research](https://cedclinic.com/cannabinoids-in-reward-processing-pain-perception/) requires rigorous pharmacological characterization and regulatory pathways similar to conventional pharmaceuticals, clinicians should remain cautious about interpreting industry restructuring as validation of specific therapeutic claims. The distinction between botanical cannabis products and standardized, single-molecule [cannabinoid therapeutics](https://cedclinic.com/medcan3-trial-cancer-symptoms/) is crucial for clinical practice, as most cannabis patients currently consume unregulated products with variable composition and potency, whereas the rare approved cannabinoid medications (such as FDA-approved formulations for seizure disorders) have undergone controlled trials. As cannabinoid research matures, practitioners should continue relying on peer-reviewed evidence and FDA-approved formulations rather than extrapolating from industry trends or emerging preclinical work. When counseling patients about cannab 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-related-research/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+InMed+Pharmaceuticals+Shifts+Focus+to+%3Cb%3ETherapeutic%3C%2Fb%3E+Programs%2C+Ends+BayMedica%27s+Non+...+%40drcaplan&url=https%3A%2F%2Fwww.geneonline.com%2Finmed-pharmaceuticals-shifts-focus-to-therapeutic-programs-ends-baymedicas-non-pharmaceutical-cannabinoid-sales%2F)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.geneonline.com%2Finmed-pharmaceuticals-shifts-focus-to-therapeutic-programs-ends-baymedicas-non-pharmaceutical-cannabinoid-sales%2F)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+InMed+Pharmaceuticals+Shifts+Focus+to+%3Cb%3ETherapeutic%3C%2Fb%3E+Programs%2C+Ends+BayMedica%27s+Non+...+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fwww.geneonline.com%2Finmed-pharmaceuticals-shifts-focus-to-therapeutic-programs-ends-baymedicas-non-pharmaceutical-cannabinoid-sales%2F)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) Related Articles - [CED Digest: 230 Items — March 15, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-clinical-relevance-2026/) - [CED Digest: 436 Items — March 14, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) - [CED Digest: 405 Items — March 12, 2026](https://cedclinic.com/alabama-medical-cannabis-sales-2026-spring-launch/) 📰 Source: [https://www.geneonline.com/inmed-pharmaceuticals-shifts-focus-to-therapeutic-programs-ends-baymedicas-non-pharmaceutical-cannabinoid-sales/](https://www.geneonline.com/inmed-pharmaceuticals-shifts-focus-to-therapeutic-programs-ends-baymedicas-non-pharmaceutical-cannabinoid-sales/) Further Reading CED Clinic Blog[Cannabis-Infused Beverages as Alcohol Alternatives: New York at Five Years](https://cedclinic.com/cannabis-beverage-substitution-alcohol-new-york-five-years/) Cannabis Policy Wire[Schedules of Controlled Substances: Temporary Placement of N-pyrrolidino metonitazene and N-pyrrolidino protonitazene in Schedule I](https://cedclinic.com/nitazene-synthetic-opioids-temporary-schedule-i-placement/) Research Digest[AM Policy Update: March 17, 2026](https://cedclinic.com/dea-synthetic-opioids-schedule-i-march-17-2026/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Cannabis Pharmaceuticals Business Research Report 2026: An $111.1 Billion Market by …](https://cedclinic.com/cannabis-pharmaceuticals-business-research-report-2026-an-111-1-billion-market-by/) An in-depth report on the growing cannabis pharmaceuticals market and its future projections. [Read the Market Report](https://cedclinic.com/cannabis-pharmaceuticals-business-research-report-2026-an-111-1-billion-market-by/) [Clinical Advancements in Cannabidiol Therapeutics and the Shift Toward Specialised Care Models](https://cedclinic.com/clinical-advancements-in-cannabidiol-therapeutics-and-the-shift-toward-specialised-care-models/) Explore recent clinical progress in cannabidiol therapeutics and evolving care models. [Explore Clinical Advances](https://cedclinic.com/clinical-advancements-in-cannabidiol-therapeutics-and-the-shift-toward-specialised-care-models/) [The Coming Divide in Cannabis: Why the U.S. Market Remains Out of Reach for Global Operators](https://cedclinic.com/cannabinoid-research-barriers-us-cannabis-market/) Analysis of market segmentation and regulatory challenges in the U.S. cannabis industry. [Read Market Analysis](https://cedclinic.com/cannabinoid-research-barriers-us-cannabis-market/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).